Form 8-K - Current report:
SEC Accession No. 0001193125-25-288770
Filing Date
2025-11-20
Accepted
2025-11-20 06:01:19
Documents
18
Period of Report
2025-11-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d33478d8k.htm   iXBRL 8-K 33818
2 EX-1.1 d33478dex11.htm EX-1.1 229245
3 EX-5.1 d33478dex51.htm EX-5.1 10846
4 EX-99.1 d33478dex991.htm EX-99.1 9675
8 GRAPHIC g33478dsp1.jpg GRAPHIC 4029
9 GRAPHIC g33478dsp4.jpg GRAPHIC 4221
10 GRAPHIC g33478g1120023425512.jpg GRAPHIC 2347
  Complete submission text file 0001193125-25-288770.txt   485387

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA nuvl-20251118.xsd EX-101.SCH 2852
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nuvl-20251118_lab.xml EX-101.LAB 17993
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nuvl-20251118_pre.xml EX-101.PRE 11262
20 EXTRACTED XBRL INSTANCE DOCUMENT d33478d8k_htm.xml XML 3638
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40671 | Film No.: 251500901
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)